Login
Companies $ABEO
$2.62 +$0.02 (0.77%) After hours
ABEONA THERAPEUTICS INC. logo

ABEONA THERAPEUTICS INC.

abeonatherapeutics.com

What Do They Do?

Licenses product-candidate rights to partners and sells ZEVASKYN, a gene-modified cell therapy for wounds caused by a rare inherited skin disease, to qualified treatment centers.

How Do They Make Money?

Licensing partners pay for product-candidate rights through upfront fees, reimbursements, option or milestone payments, and royalties; qualified treatment centers pay for ZEVASKYN after its final quality inspection.

revenue
SegmentShareRevenue
Product
Sold outright

42%
License
Licensed

58%

Who Are Their Customers?

Qualified treatment centers buy ZEVASKYN directly from Abeona under approved agreements. Third-party partners license rights to research, develop, manufacture, and commercialize product candidates.

Customers above 10% of revenue, FY2025
of revenue from two customers (48%, 46%)

Do Revenues Turn Into Profits?

Yes. Its net income in FY2025 was larger than its revenue, but spent more cash than it brought in: free cash flow was −$84.3M.

Operating income, FY2025
−1537% of revenue
▼ −39% (Loss) vs FY2024 (−$64.2M, −1512%)
Net income, FY2025
1223% of revenue
▲ Turned profitable vs FY2024 (−$63.7M, −1501%)
Free cash flow, FY2025
−1448% of revenue
▼ −44% (Loss) vs FY2024 (−$58.5M, −1377%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
Net income
▲ +7% (Loss)
vs −$5.2M in Q3 FY2025
  • Nov 6, 2026 Added oral candidate ABO-801 for eosinophilic esophagitis

Growing. Revenue grew 94% in 4 years, from $3M in FY2021 to $5.8M in FY2025, about 18% a year.

RDEB therapy commercialization The RDEB therapy moved from clinical development to commercialization: the older report describes the therapy in development, while the latest describes the approved product being commercialized for RDEB wounds.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support